What is MRKR's health score?

Marker Therapeutics, Inc. (MRKR) has a TradeApes health score of 36 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is MRKR's estimated fair value?

Based on our 5-year discounted cash flow model, Marker Therapeutics, Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is MRKR undervalued or overvalued?

Our model currently rates MRKR as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for MRKR... Refresh in a moment for the full analysis.

Marker Therapeutics, Inc. (MRKR)

Healthcare Inconclusive inconclusive weak

$1.47

Updated: 2026-06-04

TradeApes Score

Financial Strength

40 Weak

Operating Trend

30 Weak

Relative Value

40 Weak

Capital Allocation

20 Stressed

Risk

55 Mixed

Key Findings

+ Strong FCF growth — free cash flow up more than 20% year over year

Unlock Full Report →

− Sharp revenue decline — sales down more than 15% year over year

Unlock Full Report →

4 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.